A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation.

Trial Profile

A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Registrational; Therapeutic Use
  • Sponsors Cardiome Pharma
  • Most Recent Events

    • 07 Nov 2014 Primary endpoint has been met (conversion to sinus rhythm, assessed within 90 minutes after first exposure), according to a Cardiome Pharma media release.
    • 07 Nov 2014 Results published in a Cardiome Pharma media release.
    • 17 Oct 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top